**Question:** A lady presents with grade-III dyspnea. She has severe mitral stenosis with atrial fibrillation. Along with increased ventricular rate, clots in the left atrium are seen. Which of the following should not be done?

A. Administer anticoagulation therapy
B. Perform cardioversion
C. Initiate digoxin therapy
D. Start beta-blockers

**Core Concept:**
In the given scenario, we are discussing the management of a patient with severe mitral stenosis, atrial fibrillation, and increased ventricular rate due to clots in the left atrium. Severe mitral stenosis is a condition where the mitral valve does not open fully, leading to increased left-to-right pressure gradient across the valve, which results in reduced cardiac output and subsequently grade III dyspnea. The presence of atrial fibrillation and clots in the left atrium further complicates the management.

**Why the Correct Answer is Right:**
In this case, anticoagulation therapy should not be initiated. The main reason is that administering anticoagulation in patients with severe mitral stenosis, atrial fibrillation, and clots in the left atrium can lead to a paradoxical embolism. When anticoagulants are administered, clots can dislodge from the left atrium and travel to the lungs, leading to a potentially life-threatening situation called a paradoxical embolism. This involves the passage of a clot through the patent foramen ovale (a connection between the right and left atrium) and entering the systemic circulation, potentially leading to a stroke or other systemic embolism.

**Why Each Wrong Option is Incorrect:**

**A. Administer anticoagulation therapy:**
As explained above, anticoagulation therapy should not be initiated due to the risk of paradoxical embolism.

**B. Perform cardioversion:**
Cardioversion is a procedure to restore sinus rhythm in patients with atrial fibrillation. In this case, performing cardioversion might be considered, but its implementation should be carefully evaluated. The decision depends on the patient's overall health status, the nature of the clots, and the potential risk-benefit ratio.

**C. Initiate digoxin therapy:**
Digoxin is a heart rate controller that slows down the atrial rate in atrial fibrillation. In this scenario, digoxin therapy might be considered, but it should be done cautiously due to the presence of clots in the left atrium and the potential risk of paradoxical embolism.

**D. Start beta-blockers (beta-blockers):**
Beta-blockers, such as digoxin, are used to slow down the atrial rate in atrial fibrillation. In this case, beta-blockers might be considered, but as in the case of digoxin, their administration should be done cautiously due to the presence of clots in the left atrium and the potential risk of paradoxical embolism.

**Clinical Pearl:**
In patients with atrial fibrillation, particularly when there are clots in the left atrium, a